Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Nurix Therapeutics Inc

NRIX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$27.05

▼ -0.51%

Market Cap $2.81B · Vol 246.26K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.81B

Mid Cap

Div Yield

N/A

EPS Growth

+13.72%

YoY

RSI (14)

81.31

Momentum

Beta

1.82

vs Market

52W High

$27.34

1.06% below

52W Low

$8.20

230.08% above

Volume

246.26K

Avg 422.59K

P/B

3.34

Price-to-book

ROE

-49.63%

Return on equity

Free Float

92.17%

Public shares

Shariah Compliance8 STANDARDS

✗ Nurix Therapeutics Inc (NRIX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NRIX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.95%

+17.71%

+69.06%

+73.40%

YTD

+42.59%

+156.16%

+201.22%

-12.15%

Financials & Valuation

TTM · Annual

Total Revenue	$83.98M
Net Income	$-264,457,000.00
Revenue Growth (YoY)	-79.47%
Gross Margin	100.00%
Operating Margin	-340.16%
Net Profit Margin	-314.90%
ROE	-49.63%
ROA · ROIC	-38.85% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	18.25
P/B	3.34
P/FCF	N/A
EPS Growth	+13.72%
Outstanding Shares	103.78M

Technical Indicators

50-Day SMA	$22.10
200-Day SMA	$17.85
RSI (14)	81.31
Beta	1.82
52-Week High	$27.34
52-Week Low	$8.20

Volume Today	246.26K
Avg Daily Volume (30D)	422.59K
Relative Volume	0.58x
Volatility (10D)	28.25
Volatility (30D)	37.07
Free Float	92.17%

Analyst Consensus

BUY

Current Price $27.05

Mean Target $33.73

52W Low$8.20 52W High$27.34

Current

Target

$8.20 $27.34

Current Analyst target

+24.71% upside potential · 16 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00SDJ8M87

ISINUS67080M1036

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateOct 7, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and autoimmune diseases. The Company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company's portfolio of targeted protein degraders of the B?cell signaling protein BTK comprises bexobrutideg (NX?5948) and zelebrudomide (NX?2127). The Company's degradation inhibitor program includes NX-1607, an orally bioavailable inhibitor of CBL-B, an E3 ligase that regulates the activation of multiple immune cell types including T cells and NK cells. NX-1607 is targeted for immuno-oncology indications.